Search clinical trials for: HER2 negtive

Total 2788 results

Hoffmann-La Roche

Completed

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130)

Breast Cancer

United States, Korea, Republic of, Canada, United Kingdom, Australia, Belgium, Brazil, France, Slovenia, Spain, Taiwan, Japan, Italy, Argentina, India, Germany, Hungary, Russian Federation, Singapore, Ukraine, Costa Rica, Czechia, G... and more
Novartis Pharmaceuticals

Completed

Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer

Advanced Breast Cancer

United States
AstraZeneca

Not yet recruiting

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (EvoPAR-BR01)

Advanced Breast Cancer

Canada
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Withdrawn

SMMART Adaptive Clinical Treatment (ACT) Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent... and other conditions

United States
Ohio State University Comprehensive Cancer Center
Genentech, Inc.; National Comprehensive Cancer Network

Completed

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Breast Cancer

United States
Boehringer Ingelheim

Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Metastatic Breast Cancer | Esophageal Adenocarcinoma | Metastatic Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery

Breast Cancer Female
Qilu Pharmaceutical Co., Ltd.

Completed

A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

Breast Cancer

China
Centre Hospitalier Universitaire de Besancon
Pierre Fabre Medicament

Terminated

A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease (VICTORIANE)

Breast Cancer

France
Hoffmann-La Roche

Completed

A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration (ESCAPE)

Breast Cancer

Kazakhstan, Belarus
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
Seagen Inc.

Recruiting

A Study of SGN-B7H4V in Advanced Solid Tumors

Carcinoma, Non-Small-Cell Lung | Adenoid Cystic Carcinoma | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Endometrial Neoplasms | Cholangiocarcinoma | Triple Negative Breast Neoplasms | Gallbladder Carcinoma | HER2 Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms

United States, Spain, Canada, United Kingdom, Germany, Italy
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)

Breast Cancer

United States, Puerto Rico
Merck Sharp & Dohme LLC

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Breast Neoplasms

Israel, United States, Taiwan, Hong Kong, Korea, Republic of, Switzerland, Costa Rica
Genentech, Inc.

Completed

A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer

Breast Cancer, Non-small Lung Cancer

United States, Spain, Canada, Belgium
Monte Rosa Therapeutics, Inc

Recruiting

Study of Oral MRT-2359 in Selected Cancer Patients

NSCLC | Prostate Cancer | SCLC | DLBCL | High Grade Neuroendocrine Cancer | L-MYC and N-MYC Amplified Solid Tumors | NSCLC With High or Low L-MYC or N-MYC Expression | HR-positive, HER2-negative Breast Cancer

United States, Canada
Celldex Therapeutics

Completed

Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (METRIC)

Metastatic gpNMB Over-expressing Triple Negative Breast Cancer

United States, France, Spain, Italy, Canada, Germany, Australia, Belgium, United Kingdom
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors (PACT)

Sedentary Lifestyle | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC... and other conditions

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Cianna Medical, Inc.

Terminated

Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery

Stage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIC Breast Cancer | Lobular Breast Carcinoma In Situ | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Ductal Breast Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast Carcinoma and other conditions

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)

Breast Cancer

United States, Puerto Rico
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Breast Cancer

United States
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy (INAVO121)

Breast Cancer

Canada, Belgium, Korea, Republic of, United States, China, Taiwan, Mexico, Brazil, Argentina, Australia, Germany, Italy, Spain, Turkey, Thailand, South Africa, United Kingdom, France, Poland
Zhejiang Cancer Hospital
307 Hospital of PLA; Fudan University; Hangzhou Cancer Hospital; Zhejiang University and other collaborators

Unknown

A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)

Breast Cancer

China
National Cancer Institute (NCI)

Withdrawn

Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal... and other conditions
Novartis Pharmaceuticals

Completed

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Metastatic Colorectal Cancer | Gastric Cancer | Advanced Solid Tumors | Metastatic Breast Cancer | Gastroesophageal Junction Cancer | Recurrent Glioblastoma Multiforme | Advanced Pancreatic Adenocarcinoma | Safety | Triple Negative Metastatic Breast Cancer | Dose Escalation | Preliminary Efficacy | Hormone Receptor...

Canada, United Kingdom, Spain, Germany, Italy, Belgium, Australia, United States
Hoffmann-La Roche

Active, not recruiting

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) (KATE3)

Metastatic Breast Cancer

Korea, Republic of, United Kingdom, Australia, China, Croatia, Finland, France, Norway, Portugal, Slovenia, Canada, Italy, Spain, Colombia, Brazil, Poland, United States, Greece, Turkey, Russian Federation, Philippines
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Breast Cancer

Japan, Poland, United States, Australia, Belgium, Brazil, Canada, China, Colombia, Costa Rica, France, Germany, Hungary, Ireland, Israel, Korea, Republic of, New Zealand, Portugal, Puerto Rico, Russian Federation, Spain, Taiwan, Ukr... and more
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Male Breast Carcinoma | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States, Puerto Rico
Institut Claudius Regaud
Artios Pharma Ltd

Recruiting

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. (REPARP)

Breast Cancer

France
Nektar Therapeutics
Bristol-Myers Squibb

Completed

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors (PIVOT-02)

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Urothelial Carcinoma | HR+/HER2- Breast Cancer

United States, Spain, Canada, France, Italy, Belgium, Poland, United Kingdom
MacroGenics

Completed

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Cervical Cancer | Hematologic Neoplasms | Ovarian Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Small-cell Lung Cancer | TNBC - Triple-Negative Breast Cancer | HER2-positive Advanced Solid Tumors

Hong Kong, United States, Thailand, Australia, Spain, Bulgaria, Poland, Ukraine
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditions

United States
German Breast Group
Pfizer; AMS Advanced Medical Services GmbH

Recruiting

A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (PADMA)

Metastatic Breast Cancer

Germany
Pfizer

Completed

A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer

Neoplasms | Breast Neoplasms

Japan
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Breast Cancer

United States, Puerto Rico, Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Breast Cancer

United States, Puerto Rico
Genentech, Inc.

Completed

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Metastatic Breast Cancer
Baylor Research Institute

Completed

Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma

United States
Fusion Pharmaceuticals Inc.

Recruiting

A Phase 1/2 Study of [225Ac]-FPI-1434 Injection

Cervical Cancer | Breast Cancer | Ovarian Cancer | Endometrial Cancer | Uveal Melanoma | Adrenocortical Carcinoma | Advanced Solid Tumours | HER2-negative Breast Cancer | Triple Negative Breast Cancer (TNBC) | Head and Neck Squamous Cell Carcinoma (HNSCC)

United States, Australia, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Endometrial Adenocarcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast... and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

HER2-positive Breast Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Ovarian Epithelial Cancer | Stage III Ovarian Germ Cell Tumor

United States
SOLTI Breast Cancer Research Group
Novartis

Recruiting

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors (ACROPOLI)

Melanoma | Sarcoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Uterine Carcinosarcoma | Mesothelioma | Cholangiocarcinoma | Lung Adenocarcinoma | Triple Negative Breast Cancer | Epithelial Ovarian Cancer | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal... and other conditions

Spain
German Breast Group
Novartis

Unknown

Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases (RADAR)

Breast Cancer

Germany
Roswell Park Cancer Institute
National Center for Advancing Translational Sciences (NCATS)

Completed

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Prognostic Stage I Breast Cancer AJCC v8 | Prognostic... and other conditions

United States
University of Southern California
National Cancer Institute (NCI)

Recruiting

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) (EMPOWER)

Cancer | Metastatic | Breast | Triple Negative | Disseminated Tumor Cell

United States
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy (KATE2)

Metastatic Breast Cancer

United States, Korea, Republic of, United Kingdom, Germany, Spain, Taiwan, Australia, Canada, Italy
ProfoundBio US Co.

Recruiting

PRO1184 for Advanced Solid Tumors (PRO1184-001)

Ovarian Cancer | Fallopian Tube Cancer | Mesothelioma | Triple Negative Breast Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Primary Peritoneal Carcinoma | Breast Adenocarcinoma | High Grade Epithelial Ovarian Cancer | Hormone Receptor-positive/Her2 Negative Breast Cancer

United States, China
Cambridge University Hospitals NHS Foundation Trust

Unknown

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer

Breast Cancer | Perioperative/Postoperative Complications | Cardiac Toxicity

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage IIB Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer... and other conditions

United States

Search clinical trials for: HER2 negtive

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations